Series B — $125M Ask

Detecting cancer earlier saves lives

ivSYTE Diagnostics is building the world's broadest-spectrum blood-based multi-cancer early detection platform — powered by VitaSpectra AI and 200+ biomarker signatures.

CFO Dashboard Learn More
91%
Sensitivity
97%
Specificity
200+
Cancer signatures
3.2 yrs
Earlier detection
$490
Test price
Mission

The problem we are solving

Over 75% of cancers are detected at late stages when survival rates drop below 25%. Early detection is the single most impactful intervention in oncology.

Late-stage detection crisis

52% of lung cancers are detected at distant stage with only 9.7% 5-year survival. Current screening tools miss early signals entirely.

Our solution

A single blood draw analyzes 200+ biomarker signatures across RBC, immune, protein, cfDNA, and metabolomics panels — detecting cancer 3.2 years earlier.

Accessible & affordable

At $490 — nearly half the price of competitors — ivSYTE makes multi-cancer screening accessible to hospitals, clinics, and high-risk individuals alike.

AI-powered longitudinal

LSTM + Gradient Boosting models track 180+ markers over time, creating a personalised baseline and risk score delivered through a physician dashboard.

Technology

VitaSpectra AI platform

A six-step AI workflow from blood draw to physician dashboard, integrating the broadest spectrum of biomarker classes in any MCED test.

Panel 1

RBC Markers

RDW · MCV · Hgb · CAIX · Eryptosis · Band3 — 40+ cancer types, 14–36 month lead time.

Panel 2

WBC / Immune

NLR · PLR · SII · NK cells · Tregs · MDSCs · CD4/CD8 — 60+ cancer types, 12–38 months.

Panel 3

Plasma Proteins + cfDNA

CEA · CA-125 · VEGF · AFP · PSMA · KRAS · TP53 · ctDNA — 200+ types, 6–36 months.

Panel 4

Metabolomics

2-HG · Sarcosine · Kynurenine · Lactate · TEP mRNA · cfRNA-TERT — 50+ types, 10–36 months.

AI Engine

Multi-Marker AI Score

NLR + cfDNA + Metabolomics ensemble — 200+ cancer types with 24–42 month lead time.

Output

Physician Dashboard

Personalised longitudinal risk scores, flagging high-risk alerts with 97.2% confirmation rate.

Leadership

The team behind ivSYTE

A multidisciplinary team combining oncology, computational biology, AI, and business expertise.

Vani Patel
Vani Patel, MD, PhD
Founder & CEO
Oncologist & translational researcher. Former BIDMC attending physician.
Laura Carabelaian
Laura Carabelaian, PhD
Co-Founder & CSO
Cancer biology PhD. Led biomarker discovery at Dana-Farber.
Devansh Srivastava
Devansh Srivastava, PhD
Co-Founder & CTO
AI/ML engineer. Former Google DeepMind researcher in genomic models.
Mayank Gandhi
Mayank Gandhi, DBA
Chief Financial Officer
DBA Finance, Wharton. Former investment banker at Goldman Sachs covering life sciences.
Investors

Interested in ivSYTE?

We are currently raising a $125M Series B with a $40M anchor ask. Our full CFO investor dashboard covers market opportunity, revenue forecast, competitive landscape, use of proceeds, and financial projections.

View CFO Investor Dashboard →
$125M
Series B ask
~34%
Projected IRR
2029
Break-even year
$250M
Revenue by 2033
Future prospects

Road to commercial launch

From founded startup to market leader in multi-cancer early detection — a decade of disciplined execution.

2018
Done

Founded — $75M Angel

ivSYTE incorporated. Seed funding secured from angel investors to begin platform R&D.

2021
Done

Algorithm validated

VitaSpectra AI core model validated with 91% sensitivity across internal datasets.

2022
Done

Series A — $25M

First institutional funding round secured to accelerate biomarker engine development and expand the clinical team.

2023
Done

IDE obtained

Investigational Device Exemption granted by FDA for clinical trial initiation.

2024
Done

Series A2 — $50M

Series A2 extension secured to fund expanded clinical trials, MGB partnership negotiations, and compute infrastructure.

2025
Done

MGB partnership & PMA

Mass General Brigham pilot studies completed. Pre-Market Approval obtained Q4 2025.

2026
Done

VC loan — $100M

Venture debt secured to fund launch preparation: computational scale-up and headcount growth.

2028
Upcoming

Commercial launch & LCM

National rollout through hospital and clinic networks. Life cycle management begins with biomarker panel expansion.

2029+
Future

Break-even & global expansion

Reach break-even 2029, profitability 2030. Expand to EU and APAC markets. Target $250M revenue by 2033.